Clinic
Emerson Hospital
Emerson Hospital was paid $18.61M by Medicaid between Jan 2018 and Dec 2024, across 267 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 10% of everything it billed.
33Billing provider infoEMERSON HOSPITAL
CONCORD, MA 01742
CONCORD, MA 01742
33aNPI1922103357assigned 09/13/2006
33bProvider typePhysical Therapy Clinic/Center
28Total paid$18.61M
24GClaims688,767
24DCodes billed267
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Physical Therapy Clinic/Center providers in Massachusetts
Rank by total paid#2 of 28
Median peer was paid$46K
This provider vs. median406×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 73,590 | $1.92M | |
| 2019 | 82,378 | $2.21M | |
| 2020 | 80,085 | $2.07M | |
| 2021 | 111,348 | $3.03M | |
| 2022 | 120,138 | $3.36M | |
| 2023 | 120,156 | $2.89M | |
| 2024incomplete | 101,072 | $3.13M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 10% | 6,053 | 5,091 | $1.94M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.8% | 12,705 | 11,611 | $1.82M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.3% | 10,808 | 10,046 | $1.54M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.8% | 9,911 | 8,897 | $1.46M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 7.5% | 24,536 | 8,115 | $1.40M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 6.2% | 19,273 | 15,446 | $1.15M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.7% | 4,038 | 2,686 | $511K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.5% | 3,810 | 3,152 | $468K |
| 59025 | Fetal non-stress test | 2.1% | 1,525 | 682 | $398K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 2.1% | 9,532 | 3,814 | $396K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.8% | 4,096 | 1,447 | $338K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.7% | 2,898 | 2,758 | $321K |
255 more codes
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.5% | 6,573 | $286K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.5% | 2,842 | $279K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.5% | 8,841 | $279K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.5% | 9,879 | $271K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 2,569 | $268K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 1,874 | $204K |
| 77063 | Screening digital breast tomosynthesis, bilateral | 1.1% | 2,927 | $199K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,008 | $185K |
| S9485 | Crisis intervention mental health services, per diem | <1% | 307 | $164K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 38,623 | $157K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,070 | $157K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,105 | $154K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 8,798 | $151K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 219 | $148K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,718 | $148K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 8,450 | $147K |
| 97161 | <1% | 2,464 | $146K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,693 | $145K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,239 | $133K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 13,660 | $123K |
| 97803 | <1% | 1,462 | $111K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,528 | $111K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 2,689 | $108K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,640 | $103K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,649 | $100K |
| 80053 | Comprehensive metabolic panel | <1% | 32,304 | $91K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 581 | $89K |
| 83970 | <1% | 3,638 | $82K | |
| ATP14 | <1% | 12,218 | $82K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,324 | $80K |
| G0378 | Hospital observation service, per hour | <1% | 886 | $78K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 950 | $77K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,895 | $68K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,139 | $65K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 582 | $56K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,053 | $53K |
| 82728 | <1% | 6,364 | $52K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,005 | $51K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 315 | $50K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 9,949 | $49K |
| 82607 | <1% | 5,731 | $47K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,174 | $46K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,611 | $46K |
| 76642 | <1% | 569 | $45K | |
| 99205 | Prolong outpt/office vis | <1% | 233 | $37K |
| 84484 | <1% | 6,158 | $36K | |
| 84425 | <1% | 2,721 | $36K | |
| 85027 | <1% | 9,104 | $35K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 389 | $33K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 7,739 | $32K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 254 | $31K |
| 82746 | <1% | 3,589 | $31K | |
| 87081 | <1% | 5,841 | $30K | |
| 84703 | <1% | 5,800 | $30K | |
| 86780 | <1% | 2,983 | $30K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 11,720 | $28K |
| ATP17 | <1% | 3,973 | $27K | |
| 84439 | <1% | 5,113 | $27K | |
| 83550 | <1% | 5,015 | $26K | |
| 86850 | <1% | 3,950 | $25K | |
| 83540 | <1% | 6,280 | $24K | |
| 86803 | <1% | 2,430 | $24K | |
| 87077 | <1% | 4,488 | $24K | |
| 83735 | <1% | 6,939 | $23K | |
| 83013 | <1% | 504 | $23K | |
| 84134 | <1% | 2,474 | $22K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 11,717 | $22K |
| J3490 | Unclassified drugs | <1% | 1,173 | $22K |
| 83880 | <1% | 1,793 | $21K | |
| 87480 | <1% | 1,468 | $21K | |
| 87660 | <1% | 1,468 | $21K | |
| 87510 | <1% | 1,466 | $21K | |
| 83690 | <1% | 4,936 | $20K | |
| ATP08 | <1% | 4,373 | $17K | |
| 84590 | <1% | 2,311 | $17K | |
| ATP15 | <1% | 2,661 | $17K | |
| 80050 | General health panel | <1% | 1,256 | $16K |
| 85610 | <1% | 8,742 | $16K | |
| 80061 | Lipid panel | <1% | 9,995 | $15K |
| 81003 | <1% | 13,339 | $15K | |
| 86140 | <1% | 5,060 | $15K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 139 | $15K |
| 87186 | <1% | 3,059 | $14K | |
| 86618 | <1% | 1,376 | $14K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,745 | $14K |
| 85730 | <1% | 3,785 | $13K | |
| 73630 | <1% | 518 | $12K | |
| 88342 | <1% | 740 | $12K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 380 | $12K |
| 84702 | <1% | 1,017 | $12K | |
| 97162 | <1% | 263 | $11K | |
| 86900 | <1% | 3,902 | $10K | |
| 84446 | <1% | 1,066 | $10K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,055 | $9K |
| 87070 | <1% | 1,921 | $9K | |
| 87340 | <1% | 1,137 | $9K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 52 | $9K |
| 82784 | <1% | 1,059 | $8K | |
| 86901 | <1% | 3,882 | $8K | |
| 76770 | <1% | 66 | $8K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 296 | $7K |
| 84597 | <1% | 821 | $7K | |
| 74246 | <1% | 43 | $7K | |
| 85651 | <1% | 3,389 | $7K | |
| 97802 | <1% | 93 | $7K | |
| 82948 | <1% | 2,847 | $7K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 57 | $6K |
| 86762 | <1% | 517 | $6K | |
| 73610 | <1% | 181 | $6K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,945 | $6K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 37 | $5K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,915 | $5K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 144 | $5K |
| 76536 | <1% | 65 | $5K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,395 | $5K |
| 87040 | <1% | 1,238 | $5K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,478 | $5K |
| 81001 | <1% | 2,713 | $5K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 454 | $5K |
| 83605 | <1% | 966 | $4K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 13 | $4K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,651 | $4K |
| 82043 | <1% | 1,889 | $4K | |
| 73564 | <1% | 183 | $4K | |
| 83516 | <1% | 524 | $4K | |
| 93976 | <1% | 56 | $4K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 39 | $4K |
| 80076 | <1% | 3,414 | $4K | |
| 97116 | <1% | 253 | $4K | |
| 93971 | <1% | 61 | $4K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 431 | $4K |
| 93017 | <1% | 77 | $4K | |
| 84153 | <1% | 392 | $4K | |
| 87205 | <1% | 1,663 | $4K | |
| 84466 | <1% | 523 | $4K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 122 | $4K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 16 | $4K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,001 | $3K |
| 85379 | <1% | 542 | $3K | |
| 76830 | Ultrasound, transvaginal | <1% | 41 | $3K |
| 74018 | <1% | 115 | $3K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 2,788 | $3K |
| 87147 | <1% | 762 | $3K | |
| 83014 | <1% | 504 | $3K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,392 | $3K |
| 83655 | <1% | 237 | $3K | |
| 87653 | <1% | 89 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 26,863 | $3K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 76 | $2K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 778 | $2K |
| 87088 | <1% | 492 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,609 | $2K |
| ATP03 | <1% | 544 | $2K | |
| 77066 | Tomosynthesis, mammo | <1% | 39 | $2K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 30 | $2K |
| 83721 | <1% | 322 | $2K | |
| 84146 | <1% | 134 | $2K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 12 | $2K |
| 87807 | <1% | 158 | $2K | |
| 84403 | <1% | 84 | $2K | |
| 86480 | <1% | 27 | $2K | |
| 74247 | <1% | 12 | $1K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 24 | $1K |
| 74240 | <1% | 13 | $1K | |
| 86038 | <1% | 183 | $1K | |
| 82950 | <1% | 276 | $1K | |
| 84255 | <1% | 74 | $1K | |
| 82378 | <1% | 75 | $986.10 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 717 | $963.43 |
| 73030 | <1% | 43 | $955.53 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,022 | $837.59 |
| 84480 | <1% | 130 | $767.93 | |
| 84630 | <1% | 106 | $703.36 | |
| 77080 | <1% | 14 | $656.30 | |
| 84100 | <1% | 1,977 | $653.61 | |
| 81002 | <1% | 680 | $643.17 | |
| 94761 | <1% | 14,647 | $602.31 | |
| 84402 | <1% | 30 | $546.06 | |
| 82525 | <1% | 77 | $523.16 | |
| 88142 | <1% | 25 | $522.25 | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 12 | $480.02 |
| 93041 | <1% | 2,991 | $432.74 | |
| ATP07 | <1% | 93 | $430.77 | |
| 72100 | <1% | 25 | $367.75 | |
| 87899 | <1% | 59 | $358.03 | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 32 | $340.85 |
| 51798 | <1% | 96 | $329.30 | |
| 71250 | <1% | 25 | $325.07 | |
| 71045 | Radiologic examination, chest; single view | <1% | 283 | $315.10 |
| 88304 | <1% | 14 | $315.00 | |
| ATP02 | <1% | 79 | $306.23 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 111 | $298.77 |
| 84460 | <1% | 511 | $296.59 | |
| 87427 | <1% | 85 | $291.68 | |
| 85048 | <1% | 1,008 | $289.07 | |
| 82565 | <1% | 504 | $282.76 | |
| 84450 | <1% | 247 | $263.62 | |
| 80320 | <1% | 780 | $258.55 | |
| 86255 | <1% | 13 | $230.79 | |
| 86430 | <1% | 68 | $224.40 | |
| ATP18 | <1% | 47 | $197.91 | |
| 87046 | <1% | 43 | $196.81 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 12 | $193.36 |
| ATP11 | <1% | 35 | $182.20 | |
| 84550 | <1% | 384 | $176.39 | |
| 0002A | <1% | 26 | $170.34 | |
| 80164 | <1% | 56 | $152.43 | |
| Q3014 | Telehealth originating site facility fee | <1% | 446 | $144.16 |
| 87015 | <1% | 44 | $139.07 | |
| 82570 | <1% | 31 | $133.04 | |
| 87328 | <1% | 15 | $131.28 | |
| 87329 | <1% | 15 | $131.28 | |
| 82550 | <1% | 165 | $124.47 | |
| 86258 | <1% | 12 | $122.04 | |
| 81514 | <1% | 241 | $118.35 | |
| 87207 | <1% | 29 | $114.87 | |
| 83020 | <1% | 15 | $113.50 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 246 | $113.19 |
| 73130 | <1% | 12 | $107.34 | |
| 86706 | <1% | 14 | $98.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 903 | $74.32 |
| 83615 | <1% | 592 | $61.96 | |
| 83001 | <1% | 13 | $49.17 | |
| 36416 | <1% | 4,598 | $36.74 | |
| ATP10 | <1% | 13 | $35.84 | |
| 85045 | <1% | 15 | $32.96 | |
| 82040 | <1% | 112 | $31.57 | |
| 82247 | <1% | 36 | $22.15 | |
| 80178 | <1% | 13 | $20.46 | |
| 86364 | <1% | 14 | $10.17 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,129 | $7.50 |
| 82248 | <1% | 112 | $4.43 | |
| 82947 | <1% | 19 | $3.58 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 57 | $0.33 |
| 96376 | 0% | 1,208 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 514 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 122 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 383 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 505 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 31 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 13 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 16 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 39 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 111 | $0.00 |
| 84145 | 0% | 345 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 1,002 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 356 | $0.00 |
| 80323 | 0% | 286 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 138 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 280 | $0.00 |
| 84520 | 0% | 39 | $0.00 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 145 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 66 | $0.00 |
| 99238 | Hospital discharge day management, 30 minutes or less | 0% | 15 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 21 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILHELM, JACK (SR VP FINANCE &ADMIN)